Insulin efsitora alfa

Onswik, insulin efsitora alfa-gobe, LY3209590, basal insulin Fc

Metabolic & weight

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. Insulin efsitora alfa is an approved prescription medicine, not a research-only compound. This page explains the published science. Insulin can cause life-threatening low blood sugar and is not used outside clinical care; there is no community-use context for it.

1What it is

Insulin efsitora alfa takes a different route to weekly dosing than insulin icodec. Rather than attaching a fatty acid so the molecule binds albumin, efsitora fuses a single-chain insulin variant to an immunoglobulin Fc fragment — the same trick used to extend the life of many biologic drugs. The fusion protein is cleared slowly by the pathways that handle antibodies, giving a reported of about two and a half weeks and an exceptionally flat concentration profile.

Because the active insulin portion is engineered to have much reduced potency per molecule, the product is dosed in very large unit numbers at high concentrations (U-500 and U-1000 pens). The FDA approved it on 24 September 2026 as Onswik, for adults with type 2 diabetes as an adjunct to diet and exercise; it is not indicated for type 1 diabetes. Cross-link: insulin (#128), insulin icodec (#241).

2How it's thought to work

Fc-mediated persistence. The IgG Fc domain engages the neonatal Fc receptor recycling pathway, which rescues the molecule from lysosomal degradation and returns it to circulation. This is why the is measured in weeks.

Single-chain insulin design. The insulin portion is a single polypeptide rather than two disulphide-linked chains, engineered for stability in the fusion and for low enough intrinsic potency that the long exposure does not become dangerous.

Very flat profile. Peak-to-trough variation across a week is small, which is the pharmacological argument for weekly basal insulin: less day-to-day variability than daily injections in principle.

Downstream it is ordinary insulin action. on glucose uptake, hepatic glucose output and lipolysis.

Insulin fused to an antibody fragment for once-weekly dosing, reaching the same receptor by a different route to a long half-life.Schematic — not to scale

3What the research shows

Type 2 diabetes, insulin-naïve and insulin-treated

The QWINT programme comprised four open-label Phase 3 trials enrolling more than 3,400 adults with type 2 diabetes. All four met their primary endpoint of non-inferior HbA1c reduction versus a daily basal comparator (insulin glargine U100 or insulin degludec U100), with safety reported as similar to the daily comparators. QWINT-1 used the fixed-step dosing escalation described above in insulin-naïve patients; QWINT-2, QWINT-3 and QWINT-4 covered insulin-naïve patients with and without GLP-1 receptor background therapy, switching from degludec, and basal-bolus regimens respectively (Lilly QWINT reports 2024–2025; individual trial publications in NEJM and Lancet 2024–2025 †).

Graded A (did not support approval)

Type 1 diabetes

QWINT-5 compared efsitora with daily insulin degludec in type 1 diabetes and reported non-inferior HbA1c, but with a higher rate of hypoglycaemia in the efsitora arm (Bergenstal 2025, Lancet †). The US approval is restricted to type 2 diabetes, and the label states it is not for type 1. [3]

Hypoglycaemia in type 2 diabetes

Across the type 2 QWINT trials, severe or clinically significant hypoglycaemia rates were broadly similar to daily basal insulin. As with icodec, the clinically important difference is not the average rate but the inability to withdraw a dose once given.

Not gradednone published

Head-to-head against insulin icodec

No randomised comparison of the two weekly insulins has been reported. Any claim that one is better than the other rests on cross-trial comparison, which is unreliable.

4Reported side effects and interactions

Literature-reported

Hypoglycaemia is the main adverse effect. Also injection-site reactions, weight gain, hypersensitivity, peripheral oedema. Fusion proteins carry a theoretical immunogenicity concern; anti-drug antibodies were measured in the trials and did not emerge as a clinical problem in the reported data †.

Community-reported

Community use. essentially none documented.

Theoretical. the very long amplifies the concern that applies to all weekly insulin — an error, an illness, or a sudden drop in food intake plays out over many days. The high-concentration pens (U-500, U-1000) introduce a separate error risk if confused with products or drawn into an ordinary insulin syringe.

Interactions. as for insulin generally — sulfonylureas, GLP-1 receptor , SGLT2 inhibitors, corticosteroids, beta-blockers (masking symptoms), alcohol, thiazolidinediones (heart-failure risk with insulin).

Markers researchers commonly monitor

Following the label and the QWINT protocols:

Marker	Why it's watched
HbA1c	the primary efficacy measure.
Fasting plasma glucose	the titration target in QWINT-1's fixed-step escalation.
CGM time in range and time below range	the practical tool for a flat weekly insulin, and the way to see whether hypoglycaemia clusters after dosing.
Hypoglycaemia episodes with timing and severity	the key safety variable, especially in the first weeks while exposure is still rising toward steady state.
Body weight	modest gain expected.
Potassium	insulin shifts potassium intracellularly.
eGFR and liver enzymes	falling organ function reduces insulin requirement.
Anti-drug antibodies	only if an unexplained loss of effect or a hypersensitivity picture occurs; not routine.

Free for everyone. Safety information is never behind a paywall.

5Formulation and administration context

Supplied as a prefilled KwikPen in two concentrations: U-500 (500 units/mL, 1,500 units total, dosed in 5-unit increments) and U-1000 (1,000 units/mL, 3,000 units total, dosed in 10-unit increments). It is a ready-to-use solution; there is no and no self-preparation route. Injected subcutaneously once weekly on the same day each week, sites rotated. The unit numbers are not comparable to insulin units of other products on a volume basis, which is the central handling point for this drug.

6Commonly studied alongside

Metformin, SGLT2 inhibitors, GLP-1 receptor agonists including semaglutide (#3) and tirzepatide, and short-acting mealtime insulins in basal-bolus regimens. Cross-link: insulin (#128), insulin icodec (#241).

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	FDA-approved 24 September 2026 as Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes; not for type 1 diabetes
European Union	Under regulatory review; not yet authorised †
United Kingdom	Not yet licensed †
Australia	Not yet approved †
South Africa	Not registered †
Sport	Insulins are prohibited at all times by WADA (S4.5)

8Open questions

Whether the type 1 diabetes hypoglycaemia signal is a product property or a titration-protocol artefact.
How the Fc-fusion approach and the albumin-binding approach compare directly — no head-to-head trial exists.
Long-term immunogenicity over years of weekly dosing.
Whether weekly basal insulin improves adherence and outcomes enough to change when insulin is started in type 2 diabetes.

9References

1Frias JP et al. (2024). Efficacy and safety of once-weekly insulin efsitora alfa in insulin-naive type 2 diabetes (QWINT-2). NEJM. PubMed
2Rosenstock J et al. (2025). Once-weekly insulin efsitora alfa versus daily basal insulin in type 2 diabetes (QWINT-1). NEJM [verify journal]. PubMed
3Bergenstal RM et al. (2025). Once-weekly insulin efsitora alfa in type 1 diabetes (QWINT-5). Lancet [verify]. PubMed
4Kazda CM et al. (2023). Novel once-weekly basal insulin Fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 2 diabetes. Diabetes Care. PubMed · DOI
5Eli Lilly. Onswik (insulin efsitora alfa-gobe) prescribing information, 2026. PubMed
6FDA (2026). Approval of insulin efsitora alfa for adults with type 2 diabetes. PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.